Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Pain. 2010 Aug 14;151(2):378–383. doi: 10.1016/j.pain.2010.07.024

Fig. 2.

Fig. 2

Reduced spontaneous scratching following treatment with PAR-2 antibody or 5-HT2A antagonist ketanserin. A: PAR-2 antibody. AEW-treated mice received an id injection of PAR-2 antibody, or vehicle (IgG antibody) within the AEW treatment area. Graph plots mean number of scratch bouts recorded over 80 min observation period, beginning 5 min following antibody pretreatment. *: significantly different from vehicle; p<0.05, paired t-test, n=6/group). B: Ketanserin. AEW-treated mice received systemic ketanserin (3 mg/kg, ip) or vehicle (5% tween 80 in saline). The graph plots the mean number of scratch bouts recorded over an 80 min period, beginning 30 min after ketanserin or vehicle pretreatment. *: significantly different from vehicle; p<0.05, paired t-test, n=6/group).